Introduction {#s1}
============

Acute Myeloid Leukemia (AML) is the most prevalent leukemia in adults with a dismal prognosis of less than 30% 5 year survival ([@bib21]). It is a heterogeneous disease, clinically and pathologically, with common cellular themes of myeloid differentiation block, and recurrent molecular targeting of chromatin and transcriptional regulators. Effects on chromatin and transcription are reflected in the AML mutational spectrum ([@bib44]), as well as through the implication of general chromatin regulators in AML pathogenesis, in the absence of specific mutation events ([@bib66]). Specific examples of AML dependence on unmutated chromatin regulators include BRD4 ([@bib18]; [@bib89]), LSD1 ([@bib30]) or DOT1L ([@bib7]; [@bib17]), their importance highlighted by the fact that chemical inhibitors developed to target these regulators have progressed to clinical trials ([@bib26]). More recently, TAF12, a component of the basal transcription factor complex TFIID, was shown to be critical for AML cell maintenance through regulation of protein stability and activity of the transcription factor MYB ([@bib83]).

In a recent CRISPR drop-out screen of genetic dependencies in AML, we have identified several members of the promoter-bound histone acetyl-transferase SAGA complex, including acetyl-transferase *KAT2A*, as being required for AML maintenance ([@bib77]). KAT2A was suggested to impact cell survival and differentiation status, but its precise molecular mechanisms of action remain to be elucidated, and it is unclear whether it is required in AML initiation, as well as maintenance. *Kat2a* is a mammalian orthologue of yeast histone acetyl-transferase *Gcn5*, and is required for H3K9 acetylation (H3K9ac) ([@bib34]), a modification that fine-tunes, rather than initiates, locus-specific transcriptional activity. Kat2a is required for specification of mesodermal derivatives during early embryonic development ([@bib45]; [@bib80]), and for survival of neural stem and progenitor cells ([@bib49]). Loss of *Kat2a* in the hematopoietic system from an early developmental stage did not grossly impact blood formation in vivo, but could promote terminal granulocyte differentiation in vitro, through relief of protein acetylation-dependent inactivation of transcription factor Cebpa ([@bib6]). Nevertheless, detailed testing of *Kat2a* contribution to hematopoietic stem and progenitor cell function is still lacking.

Yeast Gcn5 is a classical regulator of transcriptional noise ([@bib63]), with deletion mutants enhancing cell-to-cell variability in gene expression measured across a range of locus fluorescence reporters ([@bib81]). Transcriptional noise reflects the variability in the number of mRNA molecules produced from a given locus through time; snapshot studies of gene expression capture the same phenomenon as cell-to-cell transcriptional heterogeneity ([@bib67]). Transcriptional noise can result from the bursting nature of gene expression ([@bib15]). Most if not all loci, undergo bursts of transcriptional activity with characteristic frequency and size: burst frequency corresponds to the rate at which promoters become engaged in active transcription; burst size measures the number of mRNA molecules produced during each transcriptional burst ([@bib11]). Both parameters contribute to mean gene expression, whereas transcriptional noise is more strictly dependent and shown to be anti-correlated with burst frequency ([@bib32]). In yeast, size and frequency of bursts are increased through histone acetylation of gene bodies and promoters, respectively ([@bib81]).

In functional terms, transcriptional noise has been directly implicated as a mechanism of cell fate choice in yeast ([@bib9]) and bacteria ([@bib73]), and recurrently associated, albeit correlatively, with cell fate transitions in some mammalian systems ([@bib53]). We had previously shown that normal transitions into hematopoietic lineage specification associate with cell-to-cell transcriptional heterogeneity ([@bib59]; [@bib74]). More recently, we have inhibited the activity of Kat2a in mouse embryonic stem cells, and observed an increase in transcriptional heterogeneity that impacted the stability of pluripotency with rewiring of correlation gene regulatory networks (GRNs) ([@bib54]). Whilst we have not mechanistically linked enhanced heterogeneity with loss of pluripotency, we did observe propagation of variability of transcriptional levels through the GRNs, downstream of nodes with differential H3K9ac.

Cancer, and in particular leukemia, can be perceived as a pathogenic imbalance of cell fate choices, with maintained self-renewal and reduced exit into differentiation. We postulated that enhancing transcriptional variability in AML cells, as may be achieved through *Kat2a* depletion, would enhance the probability of differentiation cell fate transitions. By using a retroviral-delivered *MLL-AF9* model of AML in a conditional *Kat2a* knockout background, we show that loss of *Kat2a* depletes AML stem-like cells, imposing a mild delay to disease initiation and severely impairing AML propagation. At a molecular level, these changes are accompanied by specific loss of H3K9 acetylation at a subset of promoters, with reduced transcription factor binding and frequency of bursting, and associated variability in transcriptional levels. Affected loci encode for general mitochondria and nucleic acid metabolism, including translation, suggesting that they may contribute to cancer fate decisions more generally, rather than in a disease-specific manner.

Results {#s2}
=======

Inducible loss of Kat2a in adult mouse hematopoiesis {#s2-1}
----------------------------------------------------

In order to investigate the impact of *Kat2a* loss on self-renewal vs. differentiation of AML stem-like cells (AML-SC), we generated an inducible conditional *Kat2a^Fl/Fl^* KO mouse model and transformed *Kat2a* excised (KO) and non-excised (WT) bone marrow (BM) cells through retroviral delivery of an *MLL-AF9* fusion transcript. This strategy allows for cellular and molecular investigation of *Kat2a* requirements during transformation, whilst minimizing putative confounding effects of acquired mutations on heterogeneity of transcription, such as might be observed in established human or mouse AML. The choice of a strong oncogenic event such as *MLL-AF9* ([@bib44]; [@bib38]; [@bib71]) minimizes the need for cooperating genetic alterations. Similarly, the option for an inducible conditional knockout may reduce compensatory effects against *Kat2a* loss. Specifically, we crossed *Kat2a^Fl/Fl^* C57Bl/6 mice ([@bib46]) on the interferon response-inducible *Mx1-Cre^+/-^* background, and generated a stable mouse line homozygous for the *Flox* allele. *Mx1-Cre*-positive (KO) and *Mx1-Cre*-negative (WT) mice were compared across all experiments ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}), with locus excision obtained through treatment of experimental and control mice with intra-peritoneal polyinosylic-polycytidylic (pIpC) acid ([@bib13]). Excision was tested 4--6 weeks after injection and consistently achieved values greater than 80% in stem and progenitor cell compartments ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}), reflected in a profound loss of gene expression, including amongst myeloid-biased (LMPP) and committed (GMP) progenitors critical for AML initiation ([@bib27]; [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Locus excision generates an in-frame product joining the first two and the last exons and is transcribed ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}) but does not code for acetyl-transferase activity or other functional domains ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). *Kat2a* was dispensable for normal mouse hematopoiesis, with minimal transient effects on the number ([Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}) and in vitro activity ([Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}) of KO hematopoietic stem cells (HSC). These effects were not sustained through aging ([Figure 1---figure supplement 1G](#fig1s1){ref-type="fig"}), and, crucially, did not affect HSC function in vivo, measured by long-term reconstitution of irradiated recipients through transplantation ([Figure 1---figure supplement 1H](#fig1s1){ref-type="fig"}).

Kat2a loss impairs establishment of MLL-AF9 leukemia {#s2-2}
----------------------------------------------------

Having verified that *Kat2a* deletion does not perturb normal hematopoiesis and thus preserves candidate progenitor cells-of-origin for leukemia transformation, we used a retroviral delivery system to express the *MLL-AF9* leukemia fusion in progenitor-enriched, lineage-depleted (Lin-) WT and KO BM cells. Cells were transformed in vitro through serial re-plating in semi-solid medium-based colony-forming assays, with similar efficiency for both genotypes ([Figure 1A](#fig1){ref-type="fig"}). Importantly, the level of locus excision was mildly increased during transformation ([Figure 1B](#fig1){ref-type="fig"}), indicating that loss of *Kat2a* does not impede the initial selection of leukemia-transformed clones. Continued re-plating revealed that *Kat2a* KO affected the type of colonies produced, with a shift from compact or type I ([@bib35]) colonies ([Figure 1C--D](#fig1){ref-type="fig"}) with Kit^+^ progenitor-like cells ([Figure 1E](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2A--B](#fig1s2){ref-type="fig"}), to mixed, or type II ([@bib35]) colonies ([Figure 1F](#fig1){ref-type="fig"}), with a characteristic halo ([Figure 1G](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2C](#fig1s2){ref-type="fig"}) of more differentiated cells and a corresponding reduction in Kit-positive cells, which have higher levels of the differentiation marker Mac1/CD11b ([Figure 1H](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2D](#fig1s2){ref-type="fig"}). Compatible with the serial re-plating experiments, cell lines established from *MLL-AF9*-transformed cell lines of both *Kat2a* WT and KO genotypes exhibited a relative gain in mixed colonies ([Figure 1---figure supplement 2E](#fig1s2){ref-type="fig"}), with higher levels of Mac1 ([Figure 1---figure supplement 2F](#fig1s2){ref-type="fig"}). Taken together, the data suggest that *Kat2a* loss is permissive to *MLL-AF9*-driven transformation, but alters the balance between in vitro self-renewal and differentiation, favoring the latter. We tested these observations in vivo by monitoring leukemia development in mice that received WT and KO Lin- BM cells transduced for 2 days with retrovirus encoding the *MLL-AF9* oncogenic fusion. *Kat2a* KO recipient animals had a moderate advantage in survival ([Figure 2A](#fig2){ref-type="fig"}), suggesting a protracted development of leukemia. Leukemias were nevertheless depleted of *Kat2a* expression ([Figure 2B](#fig2){ref-type="fig"}), thus excluding selection of escapee cells. WT and KO leukemic animals had similar disease burdens at the point of culling, as measured by organ infiltration ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}) and peripheral blood counts ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). In contrast with in vitro transformation, we did not observe gross changes to the balance between progenitor and differentiated cells in the resulting WT vs KO leukemias, which had preservation of phenotypic leukemia stem-like cells (LSC), defined by the Lin-Kit+Sca1-CD34+CD16/32+ GMP surface phenotype (L-GMP) ([Figure 2C](#fig2){ref-type="fig"}). We reckoned that loss of *Kat2a* affected the probability of leukemia development through dysregulation of transformed cells, and sought to probe this hypothesis by investigating the transcriptional programs of WT and KO leukemias at the single-cell level.

![Conditional knockout of *Kat2a* promotes differentiation of *MLL-AF9*-transformed cells in vitro.\
(**A**) Serial re-plating of colony-forming cell (CFC) assays of MLL-AF9 transformed cells, mean ± SEM, n = 3. (**B**) Excision efficiency was evaluated by qPCR during re-plating of *MLL-AF9* transformed cells, mean ± SEM, n = 2--3, \*p\<0.01 and \*\*p\<0.001. (**C**) Proportion of Compact-type colonies in *MLL-AF9* transformed cells on *Kat2a* WT or KO background, mean ± SEM, n = 3, \*p\<0.01 and \*\*p\<0.001. (**D**) Representative photograph of a Compact-type colony. (**E**) Flow cytometry analysis of the colony in (**D**). (**F**) Proportion of Mixed-type colonies in *MLL-AF9* transformed cells on *Kat2a* WT or KO background, mean ± SEM, n = 3, \*p\<0.01 and \*\*p\<0.001. (**G**) Representative photograph of a Mixed-type colony. (**H**) Flow cytometry analysis of the colony in (**G**). Two-tailed t-test was performed in (**A**), (**B**), (**C**) and (**F**).](elife-51754-fig1){#fig1}

![*Kat2a* loss impairs establishment of *MLL-AF9* leukemia in vivo.\
(**A**) Survival curve of animals transplanted with *MLL-AF9* transformed *Kat2a* WT or KO cells. N = 5 animals/genotype; log rank test, p=0.05. (**B**) Relative expression (quantitative RT-PCR) of *Kat2a* in *MLL-AF9* primary leukemia BM cells from *Kat2a* WT and KO backgrounds, mean ± SEM, n = 3, \*\*p\<0.001, 2-tailed t-test. (**C**) Flow cytometry analysis of BM cellularity of primary *Kat2a* WT or KO leukemias: shown are late (Mac1^+^Gr1^+^) and early (Mac1^+^Gr1^-^) differentiated populations and Gr1^-^Mac1^-^cKit^+^Sca1^-^CD34^+^FcgR^+^ candidate stem-like L-GMP cells, mean ± SEM, n = 4--5; 2-tailed t-test performed.](elife-51754-fig2){#fig2}

Kat2a KO leukemias have increased transcriptional variability {#s2-3}
-------------------------------------------------------------

To this end, we pooled samples from 4 to 5 primary leukemias of each genotype, sorted live GFP+ cells reporting the presence of the *MLL-AF9* fusion, and successfully sequenced over 4000 cells *Kat2a* WT and KO cells each, for a total of 13166 transcripts, using a high-throughput 10X Genomics platform ([@bib87]). Basic measures of gene alignment and quality control are summarized in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. In order to minimize the confounding effect of rarely or very low expression genes, we filtered out transcripts detected in less than 10% of all cells, and only included cells where a minimum of 500 different transcripts were detected. These filtering criteria match those recently used in analysis of heterogeneity of hematological malignancies using a similar 10X Genomics platform ([@bib57]) and were deliberately chosen for reproducibility. We thus focused the analysis on what we designated Robust gene set. These were a total of 2588 genes ([Supplementary file 2](#supp2){ref-type="supplementary-material"}), sampled from 7360 cells (3835 WT, 3525 KO), which captured general metabolic, biosynthetic and regulatory ontologies, as well as hematopoietic-specific categories, for example 'myeloid cell differentiation', indicating broad representation of transcriptional programs within the dataset ([Supplementary file 3](#supp3){ref-type="supplementary-material"}). We assessed gene expression using the D3E algorithm ([@bib20]), which makes implicit use of the single-cell nature of the data to extract information about differential dynamics of transcription, in addition to determining changes in average gene expression. The algorithm views single-cell measurements as multiple observations of the same or closely-related cells and fits a two-state promoter model that interprets gene expression measurements in terms of frequency and size of bursts of promoter activity ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). We used a multiple linear regression model to verify the contribution of burst size and frequency to average gene expression and gene expression CV in our single-cell RNA-seq data ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). In line with other studies ([@bib32]), we observed that both bursting parameters contributed to mean expression to similar extents, but there was a greater contribution of burst frequency to CV. Differential gene expression analysis between *Kat2a* WT and KO primary leukemic cells revealed mild albeit significant changes in average gene expression ([Figure 3A](#fig3){ref-type="fig"}; median difference −0.03), which were of down-regulation upon *Kat2a* excision, as might be anticipated from loss of a histone acetyl-transferase. Compatible with the proposed role of Kat2a in regulating transcriptional noise, we observed a significant increase in gene expression variability as measured by coefficient of variation (CV = standard deviation/mean) ([Figure 3B](#fig3){ref-type="fig"}; median difference 0.24) in *Kat2a* KO cells which was apparent at all levels of gene expression ([Figure 3C](#fig3){ref-type="fig"}). The increase in gene expression CV associates with greater cell-to-cell dispersion ([@bib52]), in other words reduced cell-to-cell correlation in transcript levels, amongst *Kat2a* KO leukemia cells ([Figure 3D](#fig3){ref-type="fig"}). The increased dispersion of transcriptional variability can be attributable to a change in burst frequency ([Figure 3E](#fig3){ref-type="fig"}; median difference −1.15), but not burst size ([Figure 3F](#fig3){ref-type="fig"}). This has also been observed for the *Kat2a* yeast orthologue *Gcn5* in modulating transcriptional noise ([@bib81]).

![Loss of *Kat2a* increases transcriptional heterogeneity of primary *MLL-AF9* leukemias.\
(**A**) Mean gene expression levels in *Kat2a* WT and KO primary leukemia cells. Median and 95% CI of mean gene expression levels for the 2588 genes in the Robust gene set, across 7360 cells Kolmogorov-Smirnov (KS) non-parametric test, p-value\<0.01. (**B**) Gene expression CV in *Kat2a* WT and KO primary leukemia cells. Data as in (**A**) : KS non-parametric test, p-value\<0.01. (**C**) Binned gene expression CV across the distribution of gene expression averages for *Kat2a* WT and KO primary leukemia cells, KS non-parametric test, p-value\<0.05 for all bins. (**D**) Pair-wise distance measure between any two genes across *Kat2a*-WT and KO primary leukemia cells. The top 500 most variable genes in the Robust gene set for each genotype, as determined by distance to the mean CV, were used, as previously described ([@bib52]). Welch t-test for comparison of means \*p-value\<0.01. (**E**) Distribution of burst frequencies for the Robust gene set in *Kat2a* WT and KO primary leukemias, as calculated by the D3E algorithm. KS non-parametric test, \* p-value\<0.0001. (**F**) Distribution of burst sizes for the Robust gene set in *Kat2a* WT and KO primary leukemias, as calculated by the D3E algorithm. KS non-parametric test, non-significant.\
Figure 3---source code 1.Binned CV analysis - R-language code and input matrix, source code for [Figure 3C](#fig3){ref-type="fig"}.\
Figure 3---source code 2.Pairwise distance measure - R-language code, source code for [Figure 3D](#fig3){ref-type="fig"}.\
Figure 3---source data 1.D3E output analysis of the Robust gene set with annotation of Kat2a acetylation targets.Each figure panel A, B, E and F analyzes a distinct parameter in the output file as indicated in the respective Figure; Kat2a acetylation annotation relevant for [Figure 5C](#fig5){ref-type="fig"}. Ac targets -- genes associated with promoters depleted of H3K9ac upon *Kat2a* KO; Kat2a Ac targets -- subset of acetylation targets with Kat2a binding on ENCODE.](elife-51754-fig3){#fig3}

Increased transcriptional variability associates with loss of Kat2a KO leukemia stem-like cells {#s2-4}
-----------------------------------------------------------------------------------------------

There have been several reports ([@bib52]; [@bib4]; [@bib9]; [@bib12]; [@bib14]; [@bib65]), including our own ([@bib59]), that suggest an association between variability in gene expression and probability of cell fate change, although most of the data remains correlative, at least in mammalian systems. Our recent analysis of Kat2a inhibition in mouse ES cells ([@bib54]) is compatible with this view, suggesting that the observed enhanced transcriptional variability may promote exit from pluripotency through disruption of gene regulatory networks. In this light, we asked if its enhancement in *Kat2a* KO leukemias resulted in an imbalance of self-renewal vs differentiation states that could lead to the observed delay in leukemia progression ([Figure 2A](#fig2){ref-type="fig"}). We made use of the RACE-ID algorithm ([@bib28]) to cluster the combined 7360 WT and KO cells filtered as displaying Robust gene expression, and optimally separated them into 12 clusters on the basis of the 500 most highly variable genes in each genotype ([Figure 4A](#fig4){ref-type="fig"}). Despite the occupancy of a broadly similar transcriptional space, the genotypes had differential cluster-association patterns, with some clusters, namely 7, 11 and 12, which together comprise 22.9% of WT cells, being relatively underrepresented amongst *Kat2a* KO cells (respectively 0.5, 0.2 and 0.5 of *Kat2a* WT) ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). Other clusters were over-represented amongst *Kat2a* KO cells but to a lesser extent, with only 2 over 1.5-fold (cluster 4--1.7-fold, 3.3% of WT cells; cluster 6--1.5-fold, 8.5% of WT cells), causing us to focus on the *Kat2a* KO-depleted clusters. Unsupervised alignment of the 12 clusters along a putative differentiation trajectory, shows that the underrepresented clusters lie at its undifferentiated end ([Figure 4B](#fig4){ref-type="fig"}). This is enriched for gene expression signatures associated with MLL self-renewal ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}), suggesting a depletion of cells with stem-like characteristics. Overall, gene expression programs at the start of the trajectory were similar between clusters 2, 4 and 7, with few genes unique to individual clusters thus preventing exploration of gene ontologies. There were nevertheless subtle differences in the functional categories enriched amongst differentially expressed genes between genotypes in each of the clusters, namely an association of categories associated with apoptosis in clusters 2 and 4, which were absent from cluster 7 ([Supplementary file 4](#supp4){ref-type="supplementary-material"}). The STEM-ID algorithm builds on RACE-ID to define a 'stemness' score that has successfully identified previously elusive stem cell populations in mouse pancreas ([@bib28]) and cellular hierarchies in human liver ([@bib3]). It postulates that stem cells exhibit a multitude of incipient lineage-affiliated programs (high information entropy), which are shared (high connectivity) with more differentiated cells, and attributes a 'stemness' score to each cluster as the product of entropy and number of links ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). Indeed, cluster seven scores as the most stem-like transcriptional state, suggesting that *Kat2a* KO leukemias may be depleted of functional, if not surface phenotype ([Figure 2C](#fig2){ref-type="fig"}), LSC. We tested this by pooling equal numbers of cells from all primary WT or all primary KO leukemias in [Figure 2A](#fig2){ref-type="fig"}, and transplanting them into secondary recipients at limiting cell doses. Despite the equivalent number of phenotypic LSC in the primary leukemias of both genotypes ([Figure 2C](#fig2){ref-type="fig"}), recipients of *Kat2a* KO leukemia cells failed to develop leukemia at the lowest cell doses and had a dramatically reduced frequency of functional LSC ([Figure 4C--D](#fig4){ref-type="fig"}), indicating that a requirement for Kat2a in leukemia self-renewal and/or propagation. Significantly, the level of Kat2a gene expression knockout was profound and retained in secondary leukemias, similar to the primary leukemias they originated from ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}). In agreement, the frequency of *Kat2a* KO cells escaping the excision was negligible amongst phenotypically undifferentiated Lin-Kit+Sca1-CD16/32+ cells ([Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"}). This confirmation of a maintained and profound gene expression knockout with minimum contribution from undeleted cells is particularly important, as the persistence of a rearranged transcript fusing exons 1, 2 and 18 ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}) prevents knockout quantification in the 3'-biased 10X Genomics platform. In contrast, the Taqman assay and the nested primers in the PCR analyses ([Figure 4---figure supplement 1D--E](#fig4s1){ref-type="fig"}) are directed at exons 6--7 and 11--13, respectively, which capture the excised region. Thus, cellular and molecular analyses, including inspection of transcriptional variability, are likely minimally affected by the presence of cells escaping *Kat2a* gene deletion, and should truly reflect the effects of *Kat2a* loss. Secondary leukemias, like primary leukemias, did not have a reduction in surface phenotypic LSC (L-GMP, [Figure 4E](#fig4){ref-type="fig"}), putatively highlighting a dissociation between primitive surface phenotype and function, or highlighting the existence of multiple stem-like states, as suggested by cluster-specific depletion at the undifferentiated end of the *Kat2a* KO leukemia trajectory. Nevertheless, secondary leukemias displayed an increased proportion of early (Mac1+Gr1-), but not late (Mac1+Gr1+) differentiated myelo-monocytic cells ([Figure 4E](#fig4){ref-type="fig"}), suggesting that loss of *Kat2a* may perturb self-renewal and differentiation progression at multiple levels. Accordingly, we observed reduction of transcriptional burst frequency in KO cells to be prevalent across clusters, albeit slightly more marked at the undifferentiated end ([Figure 4---figure supplement 1F](#fig4s1){ref-type="fig"}). The exception are the central clusters 11 and 12, which have minimal representation in *Kat2a* KO leukemia ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). Also, separate inspection of the differentiation trajectories for *Kat2a* WT ([Figure 4---figure supplement 2A--B](#fig4s2){ref-type="fig"}) and *Kat2a* KO cells ([Figure 4---figure supplement 2C--D](#fig4s2){ref-type="fig"}) suggests that the almost linear developmental relationship between WT leukemia cells is replaced by multiple branching decisions upon *Kat2a* loss, an observation also captured by a second pseudo-time trajectory algorithm ([Figure 4---figure supplement 2E--F](#fig4s2){ref-type="fig"}). In summary, loss of *Kat2a* depletes functional LSC and alters cellular hierarchies within *MLL-AF9* leukemia. This is likely achieved through perturbation of promoter activity and we sought to define the genes and pathways directly regulated by Kat2a.

![*Kat2a* loss depletes functional *MLL-AF9* leukemia stem-like cells.\
(**A**) t-SNE plot of single-cell RNA-seq data for *Kat2a* WT (left) and KO (right) primary leukemic cells. RACE-ID K-means clustering was used to classify cells from *Kat2a* WT and KO primary leukemias in combination, on the basis of the expression of the most highly variable genes from each genotype as defined in [Figure 2D](#fig2){ref-type="fig"}. Clusters are color-coded and cells of each genotype were displayed separately for easier appreciation of their non-overlapping transcriptional spaces. (**B**) STEM-ID trajectory plot of analysis in (**A**) representing combined measures of information entropy and cluster connectivity strength; clusters as in (**A**). (**C**) Extreme Limiting Dilution Analysis (ELDA [@bib33]) of leukemia-initiating cell frequency in *Kat2a* WT and KO primary leukemias. Primary leukemias of each genotype were pooled (WT-5; KO-4) and transplanted as 50K, 5K and 500 cell doses into 3--4 animals/dose group. (**D**) Survival curve of secondary recipients of *MLL-AF9* leukemic cells from *Kat2a* WT and KO backgrounds; data as in (**C**). Log rank test for difference in survival, n = 3--4/per dose group. 50 K cells p=0.26, 5 K cells p=0.1, 500 cells p=0.02. (**E**) Flow cytometry analysis of BM cells from secondary *Kat2a* WT and KO leukemia transplant recipients (50K and 5 K cells). Cell compartments as in [Figure 2C](#fig2){ref-type="fig"}; n = 6; mean ± SEM, 2-tailed t-test, \*\*p\<0.001, \*p\<0.01, and L-GMPs p=0.07.\
Figure 4---source code 1.tSNE plot of single-cell RNA-seq data - R-language code and individual cell coordinates with respective cluster ID, source code for [Figure 4A](#fig4){ref-type="fig"}.](elife-51754-fig4){#fig4}

Kat2a regulates transcription factor binding and bursting activity of promoters {#s2-5}
-------------------------------------------------------------------------------

We defined Kat2a regulatory targets by chromatin immunoprecipitation followed by next generation-sequencing (ChIP-seq). Kat2a is a histone acetyl-transferase required for deposition of the activating H3K9 acetylation (ac) mark ([@bib34]) and capable of catalyzing multiple acetyl-modifications ([@bib41]) at promoters and at enhancers ([@bib37]). We identified promoters as H3K4 tri-methyl (me3) peaks ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}) and enhancers with H3K4 mono-methyl (me1)- enriched regions ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}) and inspected the respective pattern of distribution of H3K9ac in pooled MLL-AF9 primary leukemias initiated by *Kat2a* KO or WT cells. Experiments were performed in duplicate, with good overlap between replicates ([Figure 5---figure supplement 1C--D](#fig5s1){ref-type="fig"}). We included analysis of another acetylation activation mark, H3K27ac, which associates with active enhancers ([@bib16]), but has not been specifically linked to Kat2a activity. Inspection of peak overlaps between methylation and acetylation marks indicated a specific depletion of H3K9ac binding at promoters in regions devoid of concomitant H3K27ac activation mark ([Figure 5A](#fig5){ref-type="fig"}). Conversely, H3K9ac was mildly increased at candidate active enhancer regions marked by the presence of H3K27ac ([Figure 5---figure supplement 1E](#fig5s1){ref-type="fig"}) suggesting a possible pattern of imbalance of H3K9ac regulation between promoters and enhancers. Guided by these preliminary observations, we focused on those promoter peaks with unique loss of H3K9ac upon *Kat2a* depletion, and used the ENCODE database ([@bib5]) to confirm enriched experimental binding of Kat2a (aka GCN5) in other model systems ([Figure 5B](#fig5){ref-type="fig"} and [Supplementary file 5](#supp5){ref-type="supplementary-material"}). Genes associated with differentially-acetylated promoter peaks represented general nucleic acid and mitochondrial metabolic categories ([Supplementary file 6](#supp6){ref-type="supplementary-material"}). Somewhat surprisingly, the list of target promoters failed to include most MLL-AF9 ChIP targets ([@bib7]) with the leukemia self-renewal associated *Hox* gene signature, namely *Hoxa9*, *Hoxa10* and *Meis1*, escaping Kat2a-dependent promoter acetylation control. This suggests that Kat2a-mediated maintenance of LSC may be achieved through general, rather than leukemia-specific, regulatory programs, with putative implications for other leukemic and non-leukemic malignancies. Having previously observed that loss of *Kat2a* associates with a decrease in frequency of transcriptional bursting ([Figure 3E](#fig3){ref-type="fig"}), we asked if this was more evident for genes dependent on Kat2a for promoter H3K9ac. Global inspection of the Robust gene set across all cells showed a similar reduction in burst frequency for Kat2a acetylation targets and non-targets ([Figure 5C](#fig5){ref-type="fig"}). However, H3K9ac target genes had uniquely preserved mean gene expression levels (95% CI KO-WT means = −0.1118 to 0.01303, Welch t-test p=0.12 for targets vs. −0.0894 to −0.0016, p=0.04 for non-targets), with increased CV upon Kat2a KO (both groups p\<0.0001), suggesting a specific impact of Kat2a on variability of transcription. Nevertheless, global analysis of transcriptional burst frequency failed to produce a specific association with Kat2a acetylation targets, which could be due to a confounding effect of mixing cells at different points in the differentiation trajectory, for which locus-specific regulation might differ, or indeed a cascading of transcriptional consequences along gene regulatory networks, as suggested by our analysis of mouse ES cells where Kat2a activity was inhibited ([@bib54]). Alternatively, the lack of association could reflect the fact that our subset of acetylation targets captures absolute, but not relative losses of promoter H3K9ac upon *Kat2a* KO, as a result of the necessarily limited replication of ChIP analysis of primary leukemia cells. To avoid potential confounding effects of cellular heterogeneity on determination of transcriptional parameters, we repeated the analysis exclusively on stem-like cluster 7 cells. Indeed, by using a more homogeneous group of cells, we could observe that the reduction in frequency of bursting in *Kat2a* KO cells was significantly more marked for H3K9ac target genes ([Figure 5D](#fig5){ref-type="fig"}; Mann-Whitney test for difference in burst frequency, Fburst, defined as (FburstKO-FBurstWT)/FburstWT p=0.0155), indeed suggesting that Kat2a acts by regulating bursting activity at target promoters. Transcriptional variability has been associated with density of transcription factor binding. As Kat2a is known to interact with transcription factors, including the oncogene Myc ([@bib80]; [@bib31]), to regulate common downstream gene expression programs, we asked if loss of Kat2a reduced transcription factor binding at target H3K9ac peaks. Analysis of H3K9ac targets using the ENCODE ChIP-Seq significance tool suggested binding by Myc in other experimental systems ([Supplementary file 3](#supp3){ref-type="supplementary-material"}), in addition to general transcription and pause-release factors. It also showed increased binding by the respiratory chain regulator Gabpa ([@bib56]) (Nrf2 in the ENCODE database), which has been described as a regulator of normal hematopoietic and Chronic Myeloid Leukemia (CML) stem cells ([@bib48]; [@bib84]). We performed ChIP-qPCR analysis of Myc and Gabpa binding at promoter peaks depleted of H3K9ac binding in *Kat2a* KO leukemias. We selected candidate Myc and Gabpa target peaks based on experimental DNA occupancy by the transcription factors (TF) across different mouse cell types in the ENCODE database. Q-PCR primers were designed under the respective H3K9ac peak, for analysis of pooled mouse *MLL-AF9* secondary leukemia samples of each genotype. We confirmed that the transcription factors (TF) Myc and Gabpa did indeed bind at most of the locations analyzed in *MLL-AF9* leukemias ([Figure 5E--F](#fig5){ref-type="fig"} and [Figure 5---figure supplement 2A--B](#fig5s2){ref-type="fig"}). Critically, we observed that binding of both TF at promoter regions dependent on Kat2a for H3K9ac was globally reduced in *Kat2a KO* leukemias ([Figure 5E--F](#fig5){ref-type="fig"}) as compared to WT (Myc: 95% CI WT-KO enrichment 0.01273 to 1.589; 2-way ANOVA p\<0.05 for genotype contribution; Gabpa: 95% CI WT-KO enrichment 0.2640 to 1.364; 2-way ANOVA p\<0.01 for genotype contribution), thus suggesting that Kat2a may regulate binding of sequence-specific TF at the promoter regions it acetylates.

![Loss of *Kat2a* depletes H3K9ac and perturbs transcription factor-binding in a subset of regulatory gene promoters.\
(**A**) Quantification of H3K9ac and H3K27ac ChIPseq peaks at H3K4me3 gene promoters in *Kat2a* WT and KO primary *MLL-AF9* leukemias. (**B**) Top ENCODE ChIP-seq Significance Tool enrichments for H3K9ac-positive promoters exclusive to *Kat2a* WT primary *MLL-AF9* leukemia cells. These promoters constitute Kat2a acetylation targets. (**C**) Distribution of burst frequencies for Kat2a acetylation targets vs. non-targets within the 2588-Robust gene set. Values as calculated by D3E with 2585 genes called differential. Mann-Whitney non-parametric test for comparison of rank medians; p\<0.0001 for *Kat2a* WT vs. KO comparisons. WT vs KO median rank differential non-significant. (**D**) Distribution of burst frequencies for Kat2a acetylation targets vs. non-targets amongst cells in cluster 7; 857 genes considered as used in RACE-ID. Burst frequencies were calculated by D3E, with 332 genes called differential. Mann-Whitney non-parametric test for comparison of rank medians; p\<0.001 for *Kat2a* WT vs. KO comparisons. (**E**) ChIP-quantitative PCR analysis of Myc binding in selected Kat2a acetylation target promoter peaks; mean values for 2--4 independent experiments using pooled BM or Spleen of *Kat2a* WT vs KO *MLL-AF9* secondary leukemias. Mean enrichments: WT = 2.158, KO = 1.357, 95% CI of difference 0.01273 to 1.589; 2-way ANOVA p\<0.05 for genotype contribution. (**F**) ChIP-quantitative PCR analysis of Gabpa binding in selected Kat2a acetylation target promoter peaks; mean values for two independent experiments using pooled BM of *Kat2a* WT vs KO *MLL-AF9* secondary leukemias. Mean enrichments: WT = 1.775, KO = 0.9609, 95% CI of difference 0.2640 to 1.364; 2-way ANOVA p\<0.01 for genotype contribution.\
Figure 5---source data 1.D3E output analysis of cluster seven with annotation of Kat2a acetylation targets.](elife-51754-fig5){#fig5}

Kat2a participates in AML maintenance through regulation of translation-associated genes {#s2-6}
----------------------------------------------------------------------------------------

Having established that Kat2a can control the H3K9ac status, and putatively TF binding, of a subset of promoters, with impact on their bursting activity, we focused on the nature of the genes showing reduced frequency of bursting in *Kat2a KO* leukemias. We found that these were preferentially associated with translation categories ([Supplementary file 7](#supp7){ref-type="supplementary-material"}), including ribosomal proteins and translation initiation and elongation factors, some of which we showed to be depleted of TF binding upon Kat2a loss. Additionally, we could observe an enrichment of translation-associated gene expression signatures amongst undifferentiated cells relatively depleted in *Kat2a* KO leukemias ([Figure 6A](#fig6){ref-type="fig"}), suggesting that they may contribute to leukemia propagation and/or maintenance. We started by verifying that perturbed regulation by Kat2a had functional consequences for the translation machinery by performing polysomal profiling of *MLL-AF9*-carrying MOLM-13 AML cells in which KAT2A activity was inhibited by the MB-3 inhibitor ([@bib77]). Reassuringly, we observed a dramatic reduction in polysomal content ([Figure 6B](#fig6){ref-type="fig"}), indicating the functional impact of Kat2a transcriptional control, despite minimum changes in average gene expression. We then tested the effect on emergent protein synthesis in mouse MLL-AF9 leukemias by quantifying OP-Puro incorporation in *Kat2a* WT and KO phenotypic L-GMP. We saw qualitative and quantitative reductions in OP-Puro incorporation in *Kat2a* KO cells, with a bimodal distribution of low and high incorporating cells that was unique to *Kat2a*-depleted cells ([Figure 6C](#fig6){ref-type="fig"}), and significantly lower levels protein synthesis within the high OP-Puro distribution ([Figure 6D](#fig6){ref-type="fig"}). Altogether, the data suggest that phenotypic leukemia stem-like cells are less translationally active in the absence of *Kat2a*, which could explain their reduced functionality. We assessed functional impact in vitro by inhibiting the translation machinery of *Kat2a* WT and KO *MLL-AF9* transformed cells with the S6K1 inhibitor PF4708671 ([@bib58]). PF4708671 targets the TOR pathway and impedes translation initiation and elongation. Treatment of *MLL-AF9* transformed primary mouse BM cultured cells with PF4708671 in colony-forming assays recaptured the imbalance between compact and mixed colonies ([Figure 6E](#fig6){ref-type="fig"}) observed upon in vitro transformation of *Kat2a* KO cells. Taken together, the data indicate that regulation of the translational machinery at least partially mediates the imbalance between self-renewal and differentiation observed in *MLL-AF9*-driven leukemia upon *Kat2a* loss. It further supports the notion that fine control of transcriptional activity leading to changes in variability of transcript levels influences cell fate transitions and can be exploited by malignant cells for cancer maintenance.

![Kat2a regulates protein synthesis activity in MLL-AF9 leukemia stem-like cells.\
(**A**) Expression of translation-associated gene signatures in individual cells along the global *MLL-AF9* STEM-ID pseudotime trajectory. Trajectory representation as in [Figure 4A](#fig4){ref-type="fig"}, with both genotypes in the same plot. Gene signature defined as per the representation of gene sets MORF_EIF4E, MORF_EIF3S2, MORF_EIF4A2, MORF_EIF3S6 (MSigDB) in the Robust geneset. (**B**) Polysomal profiling of MOLM-13 cells upon overnight treatment with DMSO or the Kat2a inhibitor MB-3 ([@bib8]) (200 μM); data are representative of 2 independent experiments. (**C**) Flow cytometry plot of OP-Puro incorporation by phenotypic L-GMP isolated from spleens of MLL-AF9 secondary leukemias WT or KO for the *Kat2a* gene. This pattern was observed in 2 out of 3 Kat2a KO leukemias analysed (0/3 WT). (**D**) Quantitation of protein synthesis rate in *Kat2a* WT and KO L-GMP as measured by OP-Puro incorporation. Mean ± SEM; n = 3 individual leukemia samples/genotype; \*p\<0.001. (**E**) Proportion of colonies types in CFC assays of *Kat2a* WT cells treated with DMSO vs. S6K1 PF4708671 inhibitor, mean + SEM, n = 3, \*\*\*p\<0.001, \*p\<0.05. 2-tailed paired t-test performed in (**D**) and (**E**).\
Figure 6---source data 1.Differential colony counts of MLL-AF9-transformed cells treated with PF4708671 S6K1 inhibitor.](elife-51754-fig6){#fig6}

Discussion {#s3}
==========

In this study, we combine functional assays with single-cell transcriptional analysis and identify a requirement for the histone acetyl-transferase Kat2a in sustaining leukemia stem-like cells (LSC) and their downstream leukemia cellular structure in *MLL-AF9*-initiated AML. Loss of *Kat2a* increases cell-to-cell variability in transcription at all levels of mean gene expression, which is reflected in poor coordination in gene expression programs in *Kat2a* KO leukemia cells. Perturbation of transcription associates with an increased trend towards differentiation in vitro and loss of long-term functional LSC in vivo. However, the differentiation routes followed by *Kat2a* KO leukemic cells are aberrant and seem to follow multiple alternative dead ends that deviate from the seemingly linear pathway of *Kat2a* WT *MLL-AF9* cells. These characteristics are reminiscent of the perturbation of pluripotency we observed in Kat2a-inhibited mouse embryonic stem (mES) cells ([@bib54]), where cells accumulate at the exit from pluripotency and only progress to differentiation with slow kinetics. Indeed, that may be the expected outcome of constitutively enhancing variability in gene expression, or transcriptional noise, which may need to be buffered downstream of a differentiation transition for differentiation to proceed ([@bib1]).

Although it is surprising that we do not observe changes to normal hematopoietic stem and progenitor cells, the same was reported by others using a tissue-specific developmental (*Vav-Cre*) knockout ([@bib6]). Stem cell and developmental systems are typically robust to noise perturbations ([@bib78]), and may have compensatory systems that buffer the loss of *Kat2a*. A putative compensatory mechanism would be the up-regulation of the *Kat2a* orthologue *Pcaf/Kat2b*, which is normally absent in HSC and progenitors. Whilst we did not observe up-regulation of *Kat2b* in leukemia cells, we did not specifically look for it in normal hematopoiesis, and cannot exclude that it may explain the difference between healthy and leukemic blood cells. We did note a very early reduction in HSC and their multilineage colony-forming potential upon *Kat2a* loss, but this was not sustained and did not affect engraftment potential, a more accurate measure of HSC activity. Also, the *Kat2a* KO hematopoietic system did not exhibit increased sensitivity to prolonged treatment with the cytotoxic drug 5-fluorouracil (data not shown), suggesting that KO and WT HSC are similarly functional. Although we cannot exclude that serial or competitive transplantation may reveal a defect in Kat2a KO HSC, our data are nevertheless supportive of a difference in the sensitivity of leukemia cells to *Kat2a* loss.

It has been proposed that cancer cells exist in a state of enhanced transcriptional activity that is required to sustain their oncogenic self-renewal programs ([@bib47]). Amongst other factors, hyper-transcription has been associated with Myc, a known collaborator of Kat2a in transcriptional regulation ([@bib31]), which is broadly required in AML ([@bib19]), including in *MLL* fusion-driven disease ([@bib68]). Accordingly, we found Myc to be depleted in a subset of promoters targeted by Kat2a. However, transcription factor depletion at promoters was not exclusive to Myc, and we made similar and indeed more extensive observations with another broad metabolic regulator, Gabpa, which has been previously characterized as a regulator of CML self-renewal ([@bib84]; [@bib86]) and associated with Kat2a-containing complexes ([@bib37]), but for which a requirement in AML has not been established. Of interest, loss of both transcription factors analysed have severe consequences to normal hematopoiesis, which are of HSC depletion in the case of Gabpa ([@bib48]; [@bib85]) and impaired differentiation with accumulation of defective phenotypic HSC in the case of Myc ([@bib82]). Notably, none of these roles is phenocopied by *Kat2a* loss. We thus suggest that Kat2a acts through co-option of the transcriptional machinery present at target loci, rather than rely on a unique conserved transcription factor circuit, to exert its pleiotropic activating effects in leukemia cells. This said, we did not observe a monotonous reduction in transcription factor binding across all loci analysed, suggesting that the presence of Kat2a may facilitate transcription factor recruitment and/or binding in a probabilistic manner, a view compatible with a role for Kat2a in stabilizing rather than initiating transcription ([@bib34]). Live-cell imaging of transcription factor recruitment to individual loci ([@bib22]) and/or single-cell ChIP ([@bib2]; [@bib29]; [@bib39]), currently undergoing significant development, will be central to definitively test this hypothesis. An alternative, albeit not mutually exclusive, explanation is that the role of Kat2a in transcription factor binding or recruitment is influenced by the chromatin context in which it acts, including the post-translational modifications it catalyses as well as the modifications introduced by other factors.

Kat2a catalyzes acetylation of Lys nine in Histone 3 (H3K9ac), a chromatin mark associated with maintenance, but not initiation, of locus transcription. Kat2a is able to catalyze acetylation of additional lysine residues in cell-free systems ([@bib41]), but its loss in vivo more specifically affects H3K9ac, particularly so in the vicinity of transcriptional start sites ([@bib80]). Compatible with these observations, Kat2a loss in the context of MLL-AF9 leukemia impacted H3K9ac specifically at gene promoters. In addition, H3K9ac was specifically lost at gene loci that do not exhibit additional activating acetylation marks such as H3K27ac. Whilst the specific meaning of single vs. double-acetylated regions is unclear, one possibility is that the presence of H3K27ac marks genomic regions that also function as enhancers of more distant genes, suggesting that Kat2a may be strictly required at promoters. In agreement with this view, we did not observe loss of H3K9ac at H3K4me1-positive enhancers. Instead, we observed a gain in H3K27ac at both H3K4me3 promoters and H3K4me1 enhancers as a single acetylation mark, which may help explain the minimal consequences of *Kat2a* loss in terms of average gene expression, and highlight the specific role of Kat2a-dependent H3K9ac of promoters in stabilizing transcriptional activity. Gain of H3K27ac may reflect differentially regulated or compensatory acetylation by other histone acetyl-transferases in the absence of Kat2a. In light of the promoter vs. enhancer specificity of the changes observed, it will be interesting to investigate to what extent reprogramming of acetylation marks reflects proximal reconfiguration of enhancer-promoter interaction via Ctcf binding. Ctcf loss has been shown to increase gene expression CV with moderate or no differences in mean expression ([@bib64]), a pattern akin to our observations upon *Kat2a* loss. Whereas their study specifically investigated sequence-driven loss of Ctcf binding at proximal, intra-TAD enhancer regions, we observed that H3K9ac-depleted promoters in *Kat2a* KO leukemia cells had a significant association with experimental Ctcf binding in ENCODE experiments, and we speculate that Ctcf may be dislodged to enhancers and promote asymmetric distribution of histone acetylation marks, with dysregulation of locus control. Of note, too, is the fact that despite the almost complete knockout of *Kat2a* expression, the loss of H3K9ac, although specific in terms of chromatin context, is far from dramatic. This is similar to recent observations in embryoid bodies ([@bib80]) and suggests that Kat2a requirement for H3K9ac is not absolute, although it may be locus-specific. Other acetyltransferases may, either normally or compensatorily, contribute to H3K9 acetylation in at least some locations, and it will be interesting to understand the parameters that determine specific dependency on Kat2a activity and its unique consequences to transcription.

Variability in gene expression levels reflects regulation of locus activity, and whilst specific contribution from enhancers has been proposed ([@bib25]) and remains an area of active investigation ([@bib42]) the role of promoter configuration and sequence has been more extensively characterized in multiple model systems ([@bib4]; [@bib23]; [@bib88]). In most if not all *loci*, transcriptional activity is discontinuous, with promoters cycling between active (ON) and inactive (OFF) states. Self-limited bursts of transcriptional activity are characterized by the burst frequency, reflecting the rate of OFF-to-ON transitions, and the burst size, which captures the number of mRNA molecules produced during each burst. In yeast, regulation of both burst parameters is dependent on H3K9ac at specific gene locations: gene body acetylation regulates burst size; promoter H3K9ac associates primarily with burst frequency ([@bib81]). Furthermore, in yeast, promoter H3K9ac is deposited by the Kat2a orthologue and founder histone acetyl-transferase Gcn5, and removed by the Sin3a orthologue Rpd3(L) deacetylase complex. Loss of Gcn5 decreases burst frequency across multiple yeast loci and has been modelled to increase intrinsic transcriptional noise, a finding we capture in mammalian cells in the present study. Whilst our study specifically links promoter H3K9ac to regulation of burst frequency in mammalian cells, recent work by the Naëf lab has shown that locus-specific manipulation of promoter, but not distal or enhancer, H3K27ac can also change transcriptional bursting frequency ([@bib55]). Although the Naëf study has not specifically manipulated H3K9ac levels, it did reveal an association between promoter H3K9ac and frequency of locus activation, which agrees with our own observations. Whether other residue-specific acetylations of promoters (or indeed enhancers) can produce the same effect remains to be determined, and this knowledge will undoubtedly deepen current understanding of transcriptional regulation. Moreover, Kat2a was recently shown to catalyze other acyl-modifications of lysine residues, namely succinylation ([@bib79]), which also associates with transcriptional activation ([@bib75]). Characterization of the exact mechanistic consequences of additional acylations and their interaction with the better characterized lysine acetylations is still lacking, not least due to lack of modification and residue-specific antibodies for the newly-identified marks. It is possible that their loss also contributes to the changes in transcriptional regulation seen upon *Kat2a* KO, and could for example explain why the reduction in frequency of bursting, although more strongly associated with loss of H3K9ac, is not exclusive to sites depleted of this modification. Additionally, it remains possible that loss of Kat2a may impact other residue-specific acylations more dramatically than its specific effect on H3K9ac and the effects of their combined loss more completely link all the effects observed. Our lab has recently developed a KAT2A-dCas9 fusion capable of catalyzing targeted acetylation events (data not shown), which will be instrumental in the mechanistic understanding of individual acetylation events and specific sequences in regulating bursting activity. It should also allow us to probe other candidate acyl modifications to unveil their unique and combined effects on transcriptional bursting.

Somewhat unexpectedly, we found that the genes regulated by Kat2a at the level of promoter acetylation, and which responded to *Kat2a* loss with decreased frequency of bursting, were specifically associated with ribosomal assembly and translation activity. Similar categories have been shown to be regulated by non-catalytic components of the Kat2a SAGA complex in controlling ESC pluripotency ([@bib69]), reinforcing the notion that Kat2a complexes impact general metabolic processes in multiple cell types, and that these general processes can specifically influence cell fate transitions. Importantly, we demonstrated that *Kat2a*-depleted leukemia stem-like cells (phenotypic L-GMP) have reduced protein synthesis activity, putatively due to a perturbation of polysomal assembly consequent to variability in levels of ribosomal proteins. Moreover, perturbation of the translational machinery could re-capture the enhanced in vitro differentiation of leukemia cells observed upon *Kat2a* depletion, suggesting that alterations in protein synthesis activity may indeed be central to exit from leukemia self-renewal. In agreement, Morrison and collaborators ([@bib70]) had previously reported that impaired protein synthesis upon genetic depletion of the ribosomal protein machinery impedes leukemia self-renewal, whilst having non-linear dose-dependent effects on normal hematopoiesis, mimicking our own observations in the *Kat2a* KO setting.

Future studies directing Kat2a catalytic activity to single or multiple loci will illuminate individual *vs.* global target gene contributions to the leukemia phenotype. However, it is tempting to speculate that the generic nature of the programs impacted by Kat2a at the level of transcriptional noise may configure an underlying propensity towards execution of cell fate transitions, which can be of a different nature in different biological contexts. Analysis of the impact of Kat2a target programs in other malignant and normal stem cell systems, or at different stages of leukemia progression will test this hypothesis. It will also be interesting to determine if other candidate regulators of transcriptional noise produce similar effects and can be exploited therapeutically in AML, as well as in other hematological and non-hematological malignancies.

Materials and methods {#s4}
=====================

Generation and analysis of *Kat2a* conditional knockout mice {#s4-1}
------------------------------------------------------------

*Kat2a^Fl/Fl^* conditional knockout mice ([@bib46]) (MGI:3801321) were bred with *Mx1-Cre* ^+/-^ transgenic mice ([@bib40]), in a C57Bl/6 background. Littermates were genotyped for *Kat2a* LoxP sites (forward: CACAGAGCTTCTTGGAGACC; reverse: GGCTTGATTCCTGTACCTCC) and for *Mx1-Cre*: (forward: CGTACTGACGGTGGGAGAAT; reverse: TGCATGATCTCCGGTATTGA): Ear notch biopsies were digested using KAPA express extract (Sigma Aldrich) and KAPA2G ROBUST HS RM Master Mix (2x) (Sigma Aldrich). PCR cycling protocol: 95C, 3 min; 40x (95°C, 15 s; 60°C, 15 s; 72°C, 60 s); 72°C, 60 s. DNA products were run on a 1% Agarose Gel in TAE (1x), at 100V and visualized using an AlphaImager UV transilluminator (Protein Simple). Cre-mediated recombination was induced in 6--10 week-old mice by administration of 5 alternate-day intraperitoneal injections of poly(I)- poly(C) (pIpC), 300 μg/dose. After pIpC treatment, animals were identified as *Kat2a* WT = *Kat2 a^Fl/Fl\ \*^ Mx1-Cre ^-/-^* and *Kat2a* KO = *Kat2 a^Fl/Fl\ \*^ Mx1-Cre ^+/-^*. Excision efficiency was determined by qPCR of genomic DNA (gDNA) from Peripheral Blood (PB), Spleen (Sp) or Bone Marrow (BM). gDNA was extracted using Blood and Tissue DNA easy Kit (Qiagen) and quantified by Nanodrop (Thermo Scientific). qPCR analysis used Sybr Green Master Mix (Applied Biosystems) and two sets of primers ([Figure 1A](#fig1){ref-type="fig"}): *Kat2a*-IN11 (forward: CAACTTCCCCAAGGTATGGA; reverse: CGGGGACCTTAGACTTGTGA), within the excised region; *Kat2a*-OUT18 (forward: AGTCTGGGCTGTTTCCATGT; reverse: GCCCGTTGTAGAATGTCTGG), distal to the second LoxP site. Expression levels were determined by the Pfaffl method following normalization to *Kat2a*-OUT. PB was collected by saphenous vein and differential blood cells counts were determined using a Vet abc automated counter (Scil Animal Care, Viernheim, Germany). Mice were kept in an SPF animal facility, and all experimental work was carried out under UK Home Office regulations. Animal research was regulated under the Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012 following ethical review by the University of Cambridge Animal Welfare and Ethical Review Body (AWERB).

Isolation of mouse BM stem and progenitor cells {#s4-2}
-----------------------------------------------

BM was isolated from mouse long bones as described before ([@bib60]). Following red blood cell lysis, total BM suspension was depleted of differentiated cells using a cocktail of biotinylated lineage (Lin) antibodies ([Table 1](#table1){ref-type="table"}) and streptavidin-labeled magnetic nanobeads (Biolegend), according to manufacturers' instructions. Cells were directly used in transplants, colony-forming assays or flow cytometry for analysis of normal hematopoiesis. For leukemia studies, cells were cultured overnight at 37°C 5% CO~2~ in RPMI supplemented with 20% Hi-FBS (R20), 2 mg/mL L-Glutamine, 1% PSA, 10 ng/mL of murine Interleukin 3 (mIL3), 10 ng/mL of murine Interleukin 6 (mIL6), and 20 ng/mL of murine Stem Cell Factor (mSCF) (cytokines from Peprotech) (supplemented R20), followed by retroviral transduction.

###### Antibodies used in flow cytometry analysis and cell sorting.

  Antibody             Fluorochrome   Catalogue \#   Clone         Dilution   Supplier
  -------------------- -------------- -------------- ------------- ---------- -------------
  CD45.1               FITC           110705         A20           1:200      BioLegend
  CD45.2               AF700          56-0454-81     104           1.:200     Ebioscience
  CD45R/B220 (Lin)\*   Biotin         103204         RA3-6B2       1:300      BioLegend
  Ter119 (Lin)\*       Biotin         116204         Ter119        1:300      BioLegend
  Gr1 (Lin)\*          Biotin         108404         RB6-8C5       1:300      Biolegend
  CD3e (Lin)\*         Biotin         100304         145--2 C11    1:300      BioLegend
  CD11b (Lin)\*        Biotin         101204         M1/70         1:300      BioLegend
  CD11b/Mac1           AF700          101222         M1/70         1:200      BioLegend
  CD11b/Mac1\*         PE-Cy7         25-0112-81     M1/70         1:200      Ebioscience
  CD16/32/FcγR\*       PE             101308         93            1:100      BioLegend
  CD16/32/FcγR         PerCP-Cy5.5    101323         93            1:100      BioLegend
  CD34\*               APC            128612         HM34          1:100      BioLegend
  CD34                 AF700          560518         RAM34         1:100      BD
  CD117/c-Kit\*        APC-Cy7        105826         2B8           1:50       BioLegend
  CD117/c-Kit          APC-eF780      47-1171-82     2B8           1:100      Ebioscience
  Sca1\*               PE-Cy7         108114         D7            1:100      BioLegend
  Gr1                  AF700          108422         RB6-8C5       1:200      BioLegend
  Gr1                  PB             108430         RB6-8C5       1:100      BioLegend
  CD135/Flt3\*         PE             135305         A2F10         1:100      BioLegend
  CD105\*              PE             562759         MJ7/18        1:100      BD
  CD150\*              Af647          562647         Q38-480       1:100      BD
  CD41\*               Biotin         13-0411-81     eBioMWReg30   1:100      Ebioscience
  Streptavidin\*       BV421          405226                       1:200      BioLegend
  Streptavidin         BV510          405233                       1:200      BioLegend

Colony forming cell (CFC) assays {#s4-3}
--------------------------------

For analysis of normal progenitors, sorted mouse BM cells were plated at a density of 200--400 cells/plate in duplicates, in MethoCult GF M3434 (STEMCELL Technologies). Colonies were scored at 7--9 days. For analysis of MLL-AF9 leukemia, retroviral-transduced BM cells were plated in M3434 at an initial density of 10000 cells/condition and scored and re-plated every 6--7 days. Re-plating was performed up to passage 9, with 4000 cells/condition used from plate 3. CFC assays from mouse MLL-AF9 transformed lines were seeded in M3434 and scored 6--7 days later. RPS6K inhibition studies were set by adding 3.3 μL DMSO, either as vehicle or with a final concentration of 3.5 μM of PF4708671 (Tocris), directly to the methylcellulose medium, with mixing prior to cell addition.

In vivo analysis of leukemia initiation and engraftment {#s4-4}
-------------------------------------------------------

For analysis of normal hematopoiesis, 10^6^ *Kat2a* WT or *Kat2a* KO cKit+ cells were intravenously injected via tail vein into lethally irradiated (2\*5.5Gy) CD45.1 recipient mice. At the described time-points, BM and Sp were collected and processed into a single-cell suspension for surface marker staining and flow cytometry analysis. For AML induction, we transplanted 1.5 × 10^6^ cKit+ *Kat2a* WT or *Kat2a* KO cells transduced with *MSCV-MLL-AF9-IRES-YFP*, intra-venous into lethally irradiated (2\* 5.5Gy) CD45.1 recipient mice. The number of recipients used was determined by the numbers of cells available post-retroviral transduction and the transduction efficiency estimated by flow cytometry at the point of injection, aiming at a minimum of 1 x 10^5^ YFP+ cells/recipient and the same number of YFP+ cells delivered to all recipients. The investigators were blinded as to the group allocation, with the injections performed by an investigator not involved in sample preparation, or in subsequent animal follow-up and tissue collection. Upon signs of illness and following human end-point criteria, animals were culled, tissue samples collected for histology analysis, and BM and Sp processed into single-cell suspensions. Flow Cytometry analysis and DNA extraction were performed. Data collection was performed using general identification numbers with no reference to the experimental group. For limiting-dilution analysis, 5\*10^2^ - 5 × 10^4^ cells from primary leukemia pooled BM of each genotype were transplanted into sub-lethally irradiated (1\*5.5Gy) CD45.1 recipient mice (3--4/dose and genotype). Numbers of animals used were contingent on availability on CD45.1 recipients aiming at no less than 10 recipients per genotype divided between 3 cell doses to allow for limiting dilution statistical analysis.

Retroviral transduction {#s4-5}
-----------------------

Retroviral construct *MSCV-MLL-AF9-IRES-YFP* was previously described ([@bib24]). For viral particle production, Human Embryonic Kidney (HEK) 293 T cells were seeded at 2.5 × 10^6^ cells/10 cm dish in DMEM supplemented with 10% Hi-FBS, 2 mg/mL L-Glutamine, 1% PSA and cultured overnight at 37°C 5% CO~2~. The following day, a transfection mix \[per plate: 47.5 µL of TranSIT (Miros), 5 µg of packaging plasmid psi Eco vector (5 µg), retroviral vector (5 µg) and 600 µL of Optimem Medium (Gibco)\] was prepared according to manufacturer's instructions and added dropwise to cells followed by plate swirling and overnight culture at 37°C 5% CO~2~. Medium was replaced with R20 the next day. At 24 and 48 hr after R20 replacement, medium was collected and filtered through a 0.45 μM syringe filter, and viral particle suspension medium was added to BM cells. BM cells from 6 to 10 week old *Kat2a* WT and *Kat2a* KO mice were collected and Lineage-depleted as described above (Isolation of mouse BM stem and progenitor cells), and cultured overnight at 37°C 5% CO~2~ in supplemented R20. For viral transduction, BM cells were briefly centrifuged at 400G, 5 min, and viral particle suspension medium supplemented with 10 ng/mL mIL3, 10 ng/mL mIL6, and 20 ng/mL mSCF added to a final density of 10^6^ cells/mL. Cells were plated in 6-multiwell plates and centrifuged for 1 hr at 2000 rpm, 32°C. After, cells were incubated for 4 hr at 37°C 5% CO~2~. A second round of viral transduction was performed, with post-centrifugation incubation performed overnight. Next day, cells were collected, pelleted and washed three times with PBS (2x) and R20 (1x). YFP level was accessed by Flow Cytometry in a Gallios Analyser (Beckman Coulter).

Establishment of MLL-AF9 transformed cell lines {#s4-6}
-----------------------------------------------

MLL-AF9 clonal liquid cultures were set up using *MLL-AF9* retrovirus-transduced primary BM cells (see Retroviral Transduction section). Transformed cells enriched in vitro by 3 rounds of serial plating (CFC assays) were maintained in R20 supplemented on alternate days with mSCF, mIL3 and mIL6, all at 20 ng/mL. Cells were cultured at 2\*10^5^ cells/ml and passaged when they reached a density of 1\*10^6^/ml.

Flow cytometry {#s4-7}
--------------

Cell surface analysis of BM and Sp was performed using a panel of antibodies marked with \* described in [Table 1](#table1){ref-type="table"}, as per the following sorting strategies: HSC - Lin^--^ cKit^+^ Sca1^+^ CD34^--^ Flt3^-^; MPP: Lin^--^ cKit^+^ Sca1^+^ CD34^+^ Flt3^-^; LMPP: Lin^--^ cKit^+^ Sca1^+^ CD34^+^ Flt3^+^; CMP: Lin^--^ cKit^+^ Sca1^-^ CD34^+/low^ CD16/32^low^; GMP: Lin^--^ cKit^+^ Sca1^+^ CD34^+^ CD16/32^high^; MEP: Lin^--^ cKit^+^ Sca1^+^ CD34^-^ CD16/32^-^; Lin^-^: CD3e^-^ B220^-^ Gr1^-^ CD11b^-^ Ter119^-^. Data were acquired on Gallios (Beckman Coulter) or LSRFortessa (BD) cytometers; data analysis used Kaluza software (Beckman Coulter). Cell sorting was performed on Influx or AriaII instruments (both from BD).

Measurement of protein synthesis {#s4-8}
--------------------------------

Six million cells each from the spleens of 3 individual secondary leukemia samples per genotype were cultured overnight in supplemented R20 to allow recovery after thaw. O-propargyl-puromycin (OP-Puro, Thermo Fisher Scientific) was added directly to 80% of each culture at a final concentration of 50 μM and incubated for 1 hr at the end of the culture period; the remainder was treated with PBS and processed in parallel as a control. After incubation, cells were washed twice in ice-cold PBS without Ca^2+^ or Mg^2+^ (Sigma), and resuspended in PBS/10%FBS for cell surface staining with Lineage markers (Gr1/Mac1-AF700), c-Kit-APC-ef780, Sca1-PE-Cy7, CD34-APC, CD16/32-PerCP-Cy5.5 (see [Table 1](#table1){ref-type="table"}) for 30 min on ice. After washing, cells were fixed in 1% paraformaldehyde (PFA) in PBS for 15 min on ice, protected from light, washed, and then permeabilized in PBS/3% FBS/0.1% saponin (permeabilization buffer) at room temperature, in the dark, for 5 min. Cells were washed and used immediately in the azide-alkyne cyclo-addition reaction with Click-iT Cell Reaction Buffer Kit (Thermo Fisher Scientific; C10269) and Alexa Fluor 555-Azide (Thermo Fisher Scientific; A20012) with a master reaction solution freshly prepared as per manufacturer's instructions for immediate use. Alexa Fluor 555-Azide was used at a final concentration of 5 μM. The reaction proceeded in the dark at room temperature for 30 min; cells were washed twice in permeabilization buffer and then counterstained with DAPI 3.3 μg/ml in PBS for 5 min prior to flow cytometry analysis. We did not observe any effect of cell cycle status on differential OP-Puro labeling.

Polysomal profiling {#s4-9}
-------------------

MOLM-13 cells (ID: CVCL_2119) were grown to an approximate density of 1 × 10^6^ cells/mL, treated with cycloheximide (100 μg/mL) for 15 min, washed in ice-cold PBS and stored at −80°C. Cells were lysed in buffer A (20 mM HEPES pH 7.5, 50 mM KCl, 10 mM (CH~3~COO)2 Mg, EDTA-free protease inhibitors (Roche), supplemented with cycloheximide 100 μg/mL, 1 mM PMSF, 100 U/mL RNase inhibitor (Promega), 1% (vol/vol) sodium deoxycholate, and 0.4% (vol/vol) NP-40) at 10^8^ cells/mL for 10 min on ice. Lysates were cleared by centrifugation (8000 g for 5 min at 4°C) and 3 A254nm units loaded onto a 10--50% (wt/vol) sucrose gradient in buffer A in Polyallomer 14 × 95 mm centrifuge tubes (Beckman). After centrifugation (Beckman SW40Ti rotor) at 260 900 g for 3 hr at 4°C, gradients were fractionated at 4°C using a Gilson Minipulse three peristaltic pump with continuous monitoring (A254nm). Samples were analysed using a Brandel gradient fractionator, the polysome profiles were detected using a UV monitor (UV-1, Pharmacia) at A254, and 0.5 mL fractions were collected. The electronic outputs of the UV-1 monitor and fraction collector were fed into a Labjack U3-LV data acquisition device with an LJTick-InAmp preamplifier.

Quantitative real time PCR (Q-RT-PCR) {#s4-10}
-------------------------------------

Total RNA was extracted using Trizol Reagent (Invitrogen). RNA from equal numbers of cells was reverse-transcribed using Superscript II (Invitrogen), following manufactures' instructions. Complementary (c)DNA was analyzed in duplicate or triplicate by qPCR using Taqman gene expression assays (*Ppia*; Mm03024003_g1; *Hprt*: Mm01545399_m1; *Kat2a*: Mm00517402_m1) and Taqman Gene Expression Mastermix (Applied Biosystems). Gene expression levels were determined by the Pfaffl method following normalization to Reference gene, as stated. For exon 2--18 in-frame products, qPCR using Sybr Green Master Mix (Applied Biosystems) was performed in triplicates. Primers used were: *Kat2a* Exon 1--2 (forward: [GTCTTCTCAGCTTGCAAGGCC]{.smallcaps}, reverse: AAAGGGTGCTCACAGCTACG); *Kat2a* Exon2-18 (forward: GTAGCTGTGAGCACCCTTTGG, reverse: TTCGCTGTCTGGGGGATTGT); *Kat2a* Exon18 (forward: CTCATCGACAAGTAGCCCCC; reverse: GTCCCTGGCTGGAGTTTCTC).

Single-cell RT-PCR {#s4-11}
------------------

*MLL-AF9* secondary leukemia cells from *Kat2a* WT and KO backgrounds were freshly thawed, stained with Lin cocktail, c-Kit-APC-ef780, Sca1-PE-Cy7, CD16/32-PerCP-Cy5.5, CD34-AF700 and Streptavidin BV510 (see [Table 1](#table1){ref-type="table"}), plus dead cell exclusion with Hoechst 32558 (Thermo Fisher Scientific), sorted as Lin^-^c-Kit^+^Sca1^-^CD16/32^+^ and single-cell deposited into 96-well plates containing 3 μl/well of 0.67% NP-40 and 2U of RNasin Plus (Promega) in RNase-free water. Plates were vortexed after deposition, centrifuged for lysate collection, and frozen immediately in dry ice. Plates were stored at −80°C. Upon thaw, cDNA was synthesized from the single-cell lysates using 5U Superscript II (Invitrogen) and 1 μM each of gene-specific primers for *Hprt* and *Kat2a* (outer reverse, [Table 2](#table2){ref-type="table"}) in a 10 μl reaction mix as per the manufacturer's protocol (42°C, 1 hr; 70°C inactivation, 15 min). The total cDNA reaction was used in a 50 μl first round PCR with duplexed outer forward primers for *Hprt* and *Kat2a* at a final concentration of 200 nM and 1.25U HotStar Taq (Qiagen) in a reaction mix as per manufacturer's protocol. Cycling conditions: 95°C, 15 min; 40\*(94°C, 1 min; 60°C, 1 min; 72°C, 2 min); 72°C, 5 min; 25°C, 30 s. Two μl of the first-round product were amplified in each of two separate second round PCR using nested primers for the two individual genes ([Table 2](#table2){ref-type="table"}). Reaction mixes as per the first round PCR, but in a final volume of 25 μl. Cycling conditions: 95°C, 15 min; 40\*(94°C, 30 s; 60°C, 1 min; 72°C, 1 min); 72°C, 5 min; 25°C, 30 s. Second-round products were run in a 2% agarose TAE1x gel at 50V, 1 hr, stained for 45--60 min in SYBRSafe solution (Thermo Fisher Scientific) in double-distilled water, and DNA visualized on a BioRad Imager.

###### Primers used for single-cell RT-PCR analysis.

                     Forward                Reverse
  ------------------ ---------------------- ------------------------
  *Hprt (outer)*     GGGGGCTATAAGTTCTTTGC   TCCAACACTTCGAGAGGTCC
  *Hprt (nested)*    GTTCTTTGCTGACCTGCTGG   TGGGGCTGTACTGCTTAACC
  *Kat2a (outer)*    CTTCCGCATGTTTCCCACTC   GATGTCTTTGGAGAAGCCCTG
  *Kat2a (nested)*   GGAAATCGTCTTCTGTGCCG   TTTGGAGAAGCCCTGCTTTTTG

Chromatin immunoprecipitation (ChIP) {#s4-12}
------------------------------------

Pools of total BM cells from MLL-AF9 *Kat2a* WT and *Kat2a* KO primary leukemia samples (ChIP-sequencing) and of total BM or spleen cells from MLL-AF9 *Kat2a* WT and *Kat2a* KO secondary leukemias (ChIP-qPCR) were crosslinked with 1% Formaldehyde Solution (Sigma Aldrich) for 10 min at room temperature (RT), with gentle rotation (50 rpm). Fixation was stopped with Glycine, and cells incubated for 5 min, RT, with gentle rotation (50 rpm), followed by two washing steps in ice-cold PBS. Cell pellets were resuspended in Lysis buffer (20 mM Hepes pH 7.6, 1% SDS and 1/100 Protease Inhibitors cocktail (PIC, Sigma Aldrich) followed by Nuclei preparation. Chromatin pellets were sheared in a Bioruptor Pico Plus (Diagenode) in TPX tubes, using 3 runs of 11 cycles (Cycle: 30 s ON 30 s OFF) on high setting. A short spin was performed between runs and samples were transferred to new TPX tubes. 2--10% of total sheared chromatin was kept for input reference. Immunoprecipitation was set up using Dilution Buffer (0.15% SDS, 1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris pH8 and 167 mM NaCl), PIC, and the respective antibody ([Table 3](#table3){ref-type="table"}) and the sheared chromatin incubated overnight at 4°C with rotation. On the following day, protein A/G magnetic beads were pre-cleared with Dilution Buffer supplemented with 0.15% SDS and 0.1%BSA, then mixed with immunoprecipitation mix and incubated for at least 4 hr at 4°C with rotation. Chromatin-Antibody-Beads mixes were sequentially washed with ChIP Wash1 (2 mM EDTA, 20 mM Tris pH8, 1% Triton X-100, 0.1% SDS and 150 mM NaCl), ChIP Wash2 (2 mM EDTA, 20 mM Tris pH8, 1% Triton X-100, 0.1% SDS and 500 mM NaCl), ChIP Wash3 (1 mM EDTA and 10 mM Tris pH8) and captured on a magnetic rack. Captured beads were incubated for 20 min with rotation in freshly prepared Elution Buffer (1% SDS and 0.1M NaHCO~3~). Supernatants were collected and decrosslinking performed overnight. DNA was column-purified using DNA clean and concentrator TM 5 KIT (Zymo Research), according to manufacturer's instructions, using 20 μL Zymo Elution Buffer. DNA quality control was performed using DNA Qubit 2.0/3.0 (Invitrogen); DNA fragment size \<500 bp (typically 200--300 bp) was confirmed by gel electrophoresis of input material on a 1.5% agarose/TAE gel.

###### Antibodies used in chromatin immunoprecipitation (ChIP).

  Antibody     Catalogue\#   Supplier
  ------------ ------------- --------------------------
  H3K27ac      Ab4729        Abcam
  H3K9ac       07--352       Millipore
  H3K4me3      Ab8580        Abcam
  H3K4me1      Ab8895        Abcam
  Myc          sc-764 x      Santa Cruz Biotechnology
  Gabpa        sc-28312      Santa Cruz Biotechnology
  rabbit IgG   12--370       Millipore
  mouse IgG    sc-2025       Santa Cruz Biotechnology

For ChIP-qPCR, eluted DNA samples were diluted 3--5 times and tested by SYBR green qPCR (primer sequences in [Table 4](#table4){ref-type="table"}) using 2 μl diluted DNA per triplicate reaction. Peak enrichments were quantified by the −2^ΔΔCt^ method relative to mouse IgG (Gabpa ChIP) or rabbit IgG (Myc ChIP), using the intergenic region in mouse chromosome 1 (*mChr1*) as a reference. Duplicate to quadruplicate ChIP experiments were analyzed. For ChIP-sequencing analysis of histone modifications, DNA from duplicate immunoprecipitation experiments and the respective input material underwent library preparation with the NextFlex Rapid DNA kit (12 cycles) at the MRC/WT Cambridge Stem Cell Institute Genomics Core Facility. After quality control, libraries were sequenced on an Illumina HiSeq 4000 sequencer at the CRUK Cambridge Research Institute, using 50bp-single-end sequencing.

###### Primers used for ChIP-quantitative PCR analysis.

                         Forward                    Reverse
  ---------------------- -------------------------- -----------------------
  *Arpc3*                GTGCGTTTATTCCTTCCGCC       TCGAATGCTTACCGGCATCT
  *Cct4*                 TGGTCTCGTTTGCAGCTTTC       TGCAGGAGACGAACTAAGGA
  *Cct7*                 AACGCTCACATCCTCCGTT        GTAGGCACAACCTGACAACC
  *Clptm1l*              GTAGGCACAACCTGACAACC       GGGTAACAAGAGAGCAGCAGA
  *Eif4e*                GCAGACCACATCAACGACTCT      TCTTTTCGCCTCCCACCATT
  *Gadd45g*              GGCATCGACTCTGACCTTGT       CGCTATGTCGCCCTCATCTT
  *Kdelr2*               CCTTGAGTGTGGCCGTCTAA       TCAATGGTGACGTGGAGCAA
  *mChr1 (intergenic)*   CATAGATGAAGCTGCCACATAGGT   GTGGGCAAGGACAAAGCATTA
  *Parl*                 CTTCGCCAGGCTCAATCTCA       ATACACACCAAGGGGCCTGA
  *Pcbp1*                AGAGCGCCTTGTGCTTTCTT       CTGGTCCTTTCGGCCAAGTA
  *Ralbp1*               GTGTTGACTTGCGGGAAACT       GCGGCTTTAACTCGGGTATG
  *Rps15*                TCCGCAAGTTCACCTACCGT       TCTGGCTCTATTTCCAGCACC
  *Rps7*                 GCTTAGAAAGAGGGACGGCT       CGGTTTCCACCCACCTACTT
  *Zbtb8oS*              ATCACCCGTTCTTCCACTGC       AGGTTTGTGCCCTTTCCGTT

ChIP-seq data analysis {#s4-13}
----------------------

Raw ChIPseq reads were analyzed on the Cancer Genomics Cloud (CGC) platform ([@bib43]). Reads were aligned to the mm10 mouse genome using the Burrows-Wheeler Aligner (BWA). Peaks from aligned reads were obtained using MACS2 peak calling algorithm with a significance q-value of 0.05. The deepTools bamCoverage command ([@bib62]) was used to determine reads enrichment relative to input; only ChIP-seq samples with clear separation from control were retained, with exclusion of one H3K4me1 and one H3K27ac replicate; consensus peaks were used for duplicate samples. To analyze changes in acetylation patterns at promoters and enhancers, H3K4me3 and H3K4me1 peaks respectively, were crossed with H3K9ac-only, H3K27ac-only and dual acetylation peaks from the corresponding genotypes. H3K9ac-only peaks associated with me3 were used for further analysis. Genomic peaks were obtained for *Kat2a* WT and *Kat2a* KO genotypes separately using Bedtools intersect ([@bib61]) and H3K4me3 K9ac peaks exclusive to WT retained as putative Kat2a peaks. Peak locations were converted to fastq sequences using UCSC table browser tool ([@bib36]). Genomic Regions Enrichment of Annotations Tool, GREAT ([@bib50]) was used to assign gene identities to the fastq sequences associated with putative Kat2a peaks, with gene promoter peaks called within - 1 kb to + 500 bp of the transcription start site (TSS). We used ENCODE ChIP-Seq Significance Tool ([@bib5]) to obtain putative transcription factor binding, including identification of genes bound by GCN5/KAT2A, to confirm the identity of putative Kat2a targets.

Single-cell RNA sequencing and data analysis {#s4-14}
--------------------------------------------

Terminal BM samples from *Kat2a* WT and *Kat2a* KO MLL-AF9 primary leukemia animals were collected (WT - 5; KO - 4) and the individual cell samples stored at −150°C. Cells were thawed and pooled for library preparation. Specifically, 12K live cells per genotype pool were sorted on an Influx sorter (BD) on the basis of YFP expression (reporting *MLL-AF9*), Hoechst 32258 exclusion (live cells) and singlet configuration (pulse width) and used for library preparation with Chromium Next GEM Single Cell 3'GEM, Library and Gel Bead Kit v1 (10XGenomics) aiming at 6K single cells per sample. Library preparation and single-end sequencing on a NextSeq 500 sequencer were done at CRUK Cambridge Research Institute. Raw single cell RNAseq fastq reads were analysed using Cellranger software (v2.1.1) to obtain the cell-gene count-matrix. Seurat ([@bib10]) was used for pre-processing the count-matrix data and obtaining differential gene expression between the two genotypes. We employed pairwise distance between gene correlations as a measure of cellular heterogeneity as described ([@bib52]), by identifying the top 500 highly variable genes in both *Kat2a* WT and KO genotypes based on distance-to-median (DM) and calculating Spearman correlation coefficients between all gene pairs. The correlation matrix was used to compute the pairwise distance measure. RaceID/StemID ([@bib28]) algorithms were used for clustering using t-SNE and obtaining pseudo-temporal arrangement of clusters based on entropy information and cluster stem scores. Monocle version 2.6.4 ([@bib76]) was used as an alternative pseudo-time analysis for *Kat2a* WT and *Kat2a* KO cells. The relative cell state ordering in Monocle was unsupervised, with leukemia self-renewal *Hoxa9* expression employed to determine the directionality of the trajectory. Parameters for the stochastic gene expression were fitted to the two-state promoter model using the D3E algorithm ([@bib20]) with the Bayesian method option for model fitting. Global normalized data were used in the Robust gene set analysis; cluster-specific parameter derivation included computation of cluster-specific normalization. A multiple linear regression of CV and average gene expression with respect to burst size and burst frequency for *Kat2a* WT and *Kat2a* KO cells were performed using lm() function in R statistical package. P-values for significant coefficients were calculated as a output of the lm() function. Scripts for integration of single-cell RNA-seq and ChIP-seq data were coded in R Language (version 3.4.4) and are provided with this submission. Gene Ontology analysis was performed with the PANTHER online tool ([@bib51]), selecting binomial analysis with Bonferroni correction. Gene sets were obtained from the Molecular Signatures Database (MSigDB) ([@bib72]) to plot gene signatures on tSNE plots. The self-renewal gene signature associated with MLL leukemia, GCM_MLL, was employed in [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}. For [Figures 6A](#fig6){ref-type="fig"} and [4](#fig4){ref-type="fig"} gene sets (MORF_EIF4E, MORF_EIF3S2, MORF_EIF4A2 and MORF_EIF3S6) were pooled to represent a translation-associated gene signature.

Statistical analysis {#s4-15}
--------------------

Statistical tests performed are specified in the figure legends. Differences were obtained with significant p-value\<0.05. Analyses were performed in statistical language R (version 3.4.4) or using Prism version 8.1.2 (GraphPad).
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**Acceptance summary:**

In this study, Pina and colleagues combined chromatin profiling and single-cell transcriptomics of a conditional KO mouse of Kat2a/Gnc5, a histone acetyltransferase central for promoter activity, to study its role in normal hematopoiesis and leukemia development. They describe that hematopoietic selective Kat2a KO does not significantly affect normal hematopoiesis; however, Kat2a KO impairs MLL-AF9-induced murine acute myeloid leukemia in vitro and in vivo by affecting the maintenance of functional leukemia stem-like cells. The authors show that Kat2a loss impacts transcription factor binding and reduces transcriptional burst frequency in a subset of gene promoters, generating enhanced variability of transcript levels. The authors suggest a new mechanism that destabilizing transcriptional variability modulates self-renewal vs differentiation of leukemia stem-like cells in acute myeloid leukemia. This study places the conceptual framework linking transcriptional variability and chromatin dysregulation to leukemia stem cell function, which will have important implications in different tumors and/or distinct stages of cancer evolution.

**Decision letter after peer review:**

Thank you for submitting your article \"Loss of Kat2a enhances transcriptional noise and depletes acute myeloid leukaemia stem like cells\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Reviewing Editor and Maureen Murphy as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this manuscript, Pina and colleagues used conditional KO mouse of Kat2a/Gnc5, a histone acetyltransferase for H3K9ac, to study its role in hematopoiesis and MLL-AF9 induced leukemia development. They first find that hematopoietic selective (by Mx1-Cre) pIpC-inducible Kat2a KO does not significantly affect normal hematopoiesis; however, Kat2a KO impairs MLL-AF9-induced murine leukemia in vitro and in vivo by affecting the maintenance of functional leukemia stem cells (LSCs). By chromatin profiling ChIP-seq and scRNA-seq analyses, the authors show that Kat2a loss increases transcriptional burst frequency and impacts TF binding such as Myc and Gabpa. The authors suggest that the above mechanisms underlie the perturbations in self-renewal vs differentiation of LSCs. Kat2a target genes were enriched with protein translation associated genes. Additionally, Kat2a inhibition in human MOLM-13 cells significantly affects polysome formation. The authors conclude that Kat2a controls transcriptional bursting in LSCs, and that destabilization of Kat2a target genes shifts leukemia cell fate from self-renewal to differentiation.

Overall this study provides several interesting findings related to the functional and mechanistic requirement of Kat2a in MLL-AF9 leukemia. This manuscript places the conceptual framework linking transcriptional noise and chromatin mutation to the cancer field. The idea that chromatin disruption, operating via increased transcriptional noise, can destabilize cell states, with the increased heterogeneity contributing to cancer evolution and drug resistance has been a popular one -- although with little real data to support it. In this study, the emphasis is more that the chromatin disruption destabilizes the cancer progression \"program\" by depleting the number of cancer stem cells, which is an interesting twist on the standard concepts. The study concludes by suggesting that the loss of the HAT can strongly drop the translational output of the cell, and in doing so, drive escape from the stem cell compartment.

The mouse genetic experiments were appropriately designed and the results were carefully analyzed. This study provides a nice addition to the existing literature, including several from the authors\' group, on the function of Kat2a in regulating transcriptional variability in stem cells (Pina et al., 2012 NCB; Teles et al., 2013; Tzelepis et al., 2016; Moris et al., 2018; etc). The overall findings also support an important role of Kat2a in regulating stem cell self-renewal vs differentiation in different model systems. The authors made other important findings, including the effects of Kat2a KO on transcriptional bursting, TF binding, and polysome formation, that increase our understanding of this important histone acetyltransferase in leukemia development. There are several important questions that need to be addressed, as detailed below, to further strengthen the main conclusions. If the remaining questions can be adequately addressed, all of the reviewers felt that this work will have a strong impact and will be of great interest to the hematopoietic, leukemia, and gene regulation communities.

Essential revisions:

1\) In assessing MLL-AF9 leukemia differentiation in vitro, the authors used serial replating of CFC assays (Figure 1). However, the description of phenotypes (e.g. compact, mixed, or dispersed) is somewhat vague and unclear, and it is important to include more quantitative measures such as flow cytometry of surface markers and/or expression of signature genes. Images of representative colonies should be provided.

2\) Figure 3: pIpC-induced Kat2a gene deletion might not be 100%. Usually, it is not a big issue for bulk RNA-seq; however, for single cell RNA-seq, this raises the concern of whether or not incomplete deletion contributes to the increased heterogeneity and transcriptional noise. As a quality control, the authors are asked to evaluate the degree of Kat2a gene deletion in various cell clusters.

3\) scRNA-seq analysis: Figure 4, it will be helpful to provide information about gene signatures and associated annotations (e.g. by GO and/or GSEA) that separate different cell clusters especially for cluster 7. This is to reveal the role for Kat2a in different cell types. In Figure 4---figure supplement 2C and D: are these effects specific to the computational method used? The authors should try one or two more trajectory plotting methods that involve different assumptions.

4\) ChIP-seq analysis: it will be helpful to provide additional justifications on the selection of H3K9ac+ only group as the focus of this study. Based on subsection "ChIP-seq data analysis", it appears that authors focused on H3K4me3 peaks with H3K9ac alone. The logic seems to be that Kat2a/Gnc5 is mainly responsible for promoter-associated H3K9ac. This decision needs to be better justified. The authors should also justify why peaks with H3K9ac+/H3K27ac+ were excluded. How about H3K9ac+ (regardless H3K27ac+ or H3K27ac-) at enhancers (H3K4me1+)? Figure 5C, the authors should comment why there is a similar burst frequency reduction for Kat2a acetylation targets and non-targets.

5\) Analysis of polysome and protein translation: One concern is that the observed polysomal content reduction may be caused by off-target effects of the inhibitor on other HATs or ribosome function. These possibilities should be discussed, and the authors should confirm these results using genetic approaches. More importantly, the MOLM-13 leukemia cell line may not recapitulate LSCs. Since the main conclusion is that Kat2a loss impairs LSC maintenance through impaired transcriptional bursting and translation, the authors should perform the analyses on WT vs Kat2a KO MLL-AF9 leukemia cells. If the cell number is limiting for polysome analysis, the authors may consider measuring protein translation directly by OP-Puro incorporation assay using established protocols (e.g. PMID: 24670665) in LSCs (e.g. L-GMPs) in vivo. If the authors could show the significant effect of protein translation in LSCs in vivo upon Kat2a KO, then these findings and conclusions would be very significant and novel.
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Author response

> Essential revisions:

*1) In assessing MLL-AF9 leukemia differentiation* in vitro*, the authors used serial replating of CFC assays (Figure 1). However, the description of phenotypes (e.g. compact, mixed, or dispersed) is somewhat vague and unclear, and it is important to include more quantitative measures such as flow cytometry of surface markers and/or expression of signature genes. Images of representative colonies should be provided.*

We agree with the reviewers that the description of colony types was incompletely documented, and thank them for pointing this out. We have included photographs of typical compact-type (revised Figure 1D) and mixed-type (revised Figure 1G) colonies, alongside representative flow cytometry profiles (revised Figure 1E and 1H, respectively). The latter document loss of progenitor-associated marker C-Kit and increase in median fluorescent intensity (MFI) of myeloid-lineage associated marker CD11b/Mac1 in mixed-type colonies. These data are described in subsection "Kat2a loss impairs establishment of MLL-AF9 leukemia". For independent validation of the morphology and surface marker characteristics of MLL-AF9-transformed colonies, we also include similar photographic and flow cytometry documentation of compact and mixed-type colonies obtained from animals that did not undergo pIpC treatment prior to bone marrow collection (Figure 1---figure supplement 2A, C and Figure 1---figure supplement 2B, D, respectively).

> 2\) Figure 3: pIpC-induced Kat2a gene deletion might not be 100%. Usually, it is not a big issue for bulk RNA-seq; however, for single cell RNA-seq, this raises the concern of whether or not incomplete deletion contributes to the increased heterogeneity and transcriptional noise. As a quality control, the authors are asked to evaluate the degree of Kat2a gene deletion in various cell clusters.

We thank the reviewers for their point, which we agree is an important one, and that we have attempted to clarify and address further both in the text (subsection "Increased transcriptional variability associates with loss of Kat2a KO leukemia stem-like cells") and in the new Figure 4---figure supplement 1A,D-E, in addition to pre-existing panels in Figure 1---figure supplement 1A, D and Figure 2B. The excision of *Kat2a* allele used in this study generates an in-frame product that joins the first 2 and the last exons (Figure 1---figure supplement 1A), and which is transcribed at levels at least similar to the full-length version of the wild-type gene (Figure 1---figure supplement 1D). Given the 3'-bias of the 10X Genomics procedure we have used for single-cell RNA sequencing in this study, we cannot reliably quantify the level of residual *Kat2a* expression in individual clusters from the sequencing data. We have nevertheless attempted to address this point experimentally in 2 ways.

1\) We have measured *Kat2a* expression in primary and secondary MLL-AF9 leukemias from *Kat2a* WT and *Kat2a* KO. We used a Taqman assay (Mm00517402_m1) targeting an amplicon at the boundary between exons 6-7, which is exclusive to the unexcised allele. Reassuringly, we see that the KO expression is more than 95% reduced compared to WT (Figure 2B), and that this level of KO is maintained even amongst the (fewer) secondary KO leukemias generated (Figure 4---figure supplement 1D) suggesting a profound locus excision with minimal contribution from cells escaping locus deletion.

2\) Perhaps more importantly, we performed single-cell RT-PCR on double-sorted Lin-Kit+ Sca1-FcgR+ cells obtained from 2 secondary leukemias/genotype generated during this study and from which we had sufficient material. We designed intron-spanning primers against exons 11-13 of *Kat2a*, again targeting a portion of the transcript included in the deletion, and multiplexed them with *Hprt* primers to perform nested single-cell RT-PCR as previously described by us in Pina et al., 2012. We analysed 88 Lin-Kit+ Sca1-FcgR+ cells/genotype and could not detect any *Kat2a* expression, while this was apparent in 79% of WT cells (Figure 4---figure supplement 1E).

Taken together, these data support minimal contribution from unexcised cells to both cellular and molecular analyses, particularly to single-cell RNA seq analysis of the stem-like cell compartments, which we explore in detail.

> 3\) scRNA-seq analysis: Figure 4, it will be helpful to provide information about gene signatures and associated annotations (e.g. by GO and/or GSEA) that separate different cell clusters especially for cluster 7. This is to reveal the role for Kat2a in different cell types. In Figure 4---figure supplement 2C and D: are these effects specific to the computational method used? The authors should try one or two more trajectory plotting methods that involve different assumptions.

We thank the reviewers for raising these points that undoubtedly inform and add detail to our scRNA-seq analysis of *Kat2a* loss.

Concerning the point on cluster-specific gene annotations, we include 2 additional panels as the revised Figure 4---figure supplement 1B and revised Figure 6A, which demonstrate an association between the stem-most clusters 2, 4 and 7 as defined by STEM-ID and gene sets associated with MLL-associated self-renewal (GCM-MLL) -- Figure 4---figure supplement 1B -- and with translation-associated genes (MORF_EIF4E, MORF_EIF3S2, MORF_EIF4A2 and MORF_EIF3S6) -- Figure 6A. These data reinforce the notion of the stem-like nature of the cells in those clusters, as well as their association with translational machinery, which we show in this manuscript to be targeted by *Kat2a* loss. We found cluster-specific gene annotations to be of limited value due to the reduced number of unique cluster-defining genes. However, we did perform analysis of genes differential between WT and KO cells (as per D3E) in each of the clusters. There is considerable overlap in enriched categories between clusters, although clusters 2 and 4 have clearer associations with cell death / apoptosis, which are not present as enriched differential categories in cluster 7. These data have been included as Supplementary file 4, and are referred to in subsection "Increased transcriptional variability associates with loss of Kat2a KO leukemia stem-like cells".

In response to reviewers' comments, we also employed Monocle to infer differentiation trajectories in *Kat2a* WT and *Kat2a* KO leukaemias (revised Figure 4---figure supplement 2E and F, respectively, called in subsection "Increased transcriptional variability associates with loss of Kat2a KO leukemia stem-like cells"). Monocle-inferred trajectory of *Kat2a* KO leukemia denotes more extensive branching from the self-renewal arm and disconnection between early and late arms of differentiation compatible with the heterogeneity of fate decisions captured by STEM-ID. Significantly, the same cells are captured by both methods at the start and end of the WT and KO trajectories, reinforcing the robustness of the conclusions.

> 4\) ChIP-seq analysis: it will be helpful to provide additional justifications on the selection of H3K9ac+ only group as the focus of this study. Based on subsection "ChIP-seq data analysis", it appears that authors focused on H3K4me3 peaks with H3K9ac alone. The logic seems to be that Kat2a/Gnc5 is mainly responsible for promoter-associated H3K9ac. This decision needs to be better justified. The authors should also justify why peaks with H3K9ac+/H3K27ac+ were excluded. How about H3K9ac+ (regardless H3K27ac+ or H3K27ac-) at enhancers (H3K4me1+)? Figure 5C, the authors should comment why there is a similar burst frequency reduction for Kat2a acetylation targets and non-targets.

We note the reviewers' point and have explained further our focus on H3K4me3+ H3K9ac-only peaks as targeted by Kat2a. The choice was entirely guided by the data and not justified a posteriori by it, as explained in more detail in subsection "Kat2a regulates transcription factor binding and bursting activity of pro". Kat2a acetylation activity has been associated with H3K9ac of promoters, a finding recently reiterated by Sharon Dent's group in embryoid bodies (Wang et al., 2018) and ourselves in ES cells (Moris et al., 2018). However, earlier reports suggested that Kat2a might also exert H3K9ac activity at enhancers, specifically in the context of the ATAC acetylation complex (Krebs et al., 2011), and we interrogated both promoters (Figure 5A) and enhancers (revised Figure 5---figure supplement 1E) for Kat2a-dependent (K9) and non-Kat2a-dependent (K27) acetylation marks. Analysis of co-localized peaks indicated that promoter H3K9ac alone was specifically lost upon *Kat2a* KO. The same was not true at H3K4me1+ enhancers, or of H3K27ac, thus directing our focus to promoter H3K9ac-only peaks.

Additionally, we have commented further on the reduction in burst frequency amongst *Kat2a* non-targets (revised Figure 5C) by advancing potential explanations (subsection "Kat2a regulates transcription factor binding and bursting activity of pro"): 1. We have focused on loss of peak detection rather than reduction in peak intensity, making it likely that some Kat2a target regions may have been missed by our analysis and thus considered amongst Kat2a non-target peaks. 2. Also, Figure 5C estimation of burst frequency uses all cells, rather than putatively functionally identical cells according to clusters as in Figure 5D: it is possible that the underlying functional heterogeneity erode differences between genotypes. 3. We have previously shown that transcriptional noise is propagated through gene regulatory networks to downstream target genes that are not directly regulated by Kat2a (Moris et al., 2018). The fact that the analysis in revised Figure 5C uses all the cells makes it more likely that downstream regulatory connections are captured in the data and may contribute to differences in burst frequency between genotypes. 4. Finally, we cannot exclude that loss of *Kat2a* impact other histone lysine acylations with transcriptional consequences similar to those of acetylation: a recent example is lysine succinylation, which has not been explored globally or in the context of leukaemia, and is an interesting research avenue in the future. This latter point is highlighted in the Discussion section.

*5) Analysis of polysome and protein translation: One concern is that the observed polysomal content reduction may be caused by off-target effects of the inhibitor on other HATs or ribosome function. These possibilities should be discussed, and the authors should confirm these results using genetic approaches. More importantly, the MOLM-13 leukemia cell line may not recapitulate LSCs. Since the main conclusion is that Kat2a loss impairs LSC maintenance through impaired transcriptional bursting and translation, the authors should perform the analyses on WT vs Kat2a KO MLL-AF9 leukemia cells. If the cell number is limiting for polysome analysis, the authors may consider measuring protein translation directly by OP-Puro incorporation assay using established protocols (e.g. PMID: 24670665) in LSCs (e.g. L-GMPs)* in vivo*. If the authors could show the significant effect of protein translation in LSCs* in vivo *upon Kat2a KO, then these findings and conclusions would be very significant and novel.*

We thank the reviewers for their comments, which have indeed strengthened our findings. We have performed OP-Puro incorporation experiments ex vivo using cells isolated from the spleens of MLL-AF9 *Kat2a* WT and KO secondary leukemias produced by this study. We have included the results in revised Figure 6C-D, with the data reported in subsection "Kat2a participates in AML maintenance through regulation of translation-associated 1 genes "and discussed in subsection "Kat2a participates in AML maintenance through regulation of translation-associated 1 genes". We observed a reduction in OP-Puro incorporation, that was both of fraction of incorporating (i.e. actively translating) cells and the amount incorporated (i.e. level of activity) in *Kat2a* KO leukemia cells with an L-GMP phenotype. Incidentally, we have also made similar observations in another AML model upon *Kat2a* KO (data not shown), suggesting a specific Kat2a-mediated effect worth exploring in the future.
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